Enthesitis-Related Arthritis

The FDA has approved secukinumab for the treatment of active psoriatic arthritis in patients aged 2 years and older, and for active enthesitis-related arthritis in those aged 4 years and older.

Guselkumab is associated with durable improvements in multiple psoriatic disease domains through 2 years, with no new safety findings, in patents who are biologic-naïve, according to data published in Arthritis & Rheumatology.

Secukinumab is efficacious in children and adolescents with psoriatic arthritis and enthesitis-related arthritis, resulting in a significantly longer time to flare versus placebo, according to data presented at ACR Convergence 2021.

Enthesitis-related arthritis and a family history of autoimmune disease are key risk factors for inflammatory bowel disease in juvenile idiopathic arthritis, according to data published in Rheumatology.

There is significant variation in the patterns of methotrexate use prior to initiating etanercept in patients with juvenile idiopathic arthritis, according to registry data published in Pediatric Rheumatology.

Secukinumab yielded a significantly longer time to flare than placebo in pediatric patients with enthesitis-related arthritis and juvenile psoriatic arthritis, according to findings presented at the EULAR 2021 Congress.

Treatment with guselkumab results in higher enthesitis resolutions rates at week 24, with maintenance of those higher rates through 1 year, in patients with psoriatic arthritis, according to data published in Rheumatology.

More than half of patients with psoriatic arthritis experience a two-year delay from symptom onset to diagnosis, especially younger patients, those who are obese and those with enthesitis, noted data published in The Journal of Rheumatology.

Patients with psoriatic arthritis have much to be hopeful about, with understanding of the disease increasing and an expanded range of treatment options available, according to a presenter at the 2020 Rheumatology Nurses Society Annual Conference.